Compare MNTK & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNTK | NYXH |
|---|---|---|
| Founded | 1980 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.2M | 190.6M |
| IPO Year | 2020 | 2021 |
| Metric | MNTK | NYXH |
|---|---|---|
| Price | $1.35 | $3.14 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $3.33 | ★ $11.67 |
| AVG Volume (30 Days) | ★ 209.6K | 56.7K |
| Earning Date | 06-22-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $176,382,000.00 | N/A |
| Revenue This Year | $17.70 | $97.32 |
| Revenue Next Year | $16.52 | $241.74 |
| P/E Ratio | $141.00 | ★ N/A |
| Revenue Growth | ★ 0.37 | N/A |
| 52 Week Low | $1.21 | $3.37 |
| 52 Week High | $2.78 | $11.87 |
| Indicator | MNTK | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 35.19 | 28.09 |
| Support Level | N/A | N/A |
| Resistance Level | $1.79 | $5.02 |
| Average True Range (ATR) | 0.11 | 0.27 |
| MACD | -0.03 | -0.08 |
| Stochastic Oscillator | 25.96 | 1.47 |
Montauk Renewables Inc is a renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments namely Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.